HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB ON BACKGROUND METHOTREXATE IN RHEUMATOID ARTHRITIS: BLINDED TWO-YEAR RESULTS FROM THE AMPLE STUDY

被引：0
|
作者：
Weinblatt, Michael E. [1 ]
Schiff, Michael H. [2 ]
Valente, Robert [3 ]
van der Heijde, Desiree [4 ]
Citera, Gustavo [5 ]
Elegbe, Ayanbola [6 ]
Maldonado, Michael A. [7 ]
Fleischmann, Roy [8 ]
机构：
[1] Brigham & Womens Hosp, Dept Rheumatol & Immunol, Boston, MA 02115 USA
[2] Univ Colorado, Div Rheumatol, Denver, CO USA
[3] Arthritis Ctr Nebraska, Dept Rheumatol, Lincoln, NE USA
[4] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[5] Inst Rehabil Psicofis, Rheumatol Sect, Buenos Aires, DF, Argentina
[6] Bristol Myers Squibb, Dept Global Biometr Sci, Princeton, NJ USA
[7] Bristol Myers Squibb, Dept Med Affairs, Princeton, NJ USA
[8] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
来源：
RHEUMATOLOGY | 2014年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
86
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration
    Schiff, Michael H.
    Jaffe, Jonathan S.
    Freundlich, Bruce
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1549 - 1551
  • [32] Head-to-Head, Randomised, Crossover Study of Oral versus Subcutaneous Methotrexate in Patients with Rheumatoid Arthritis: Drug-Exposure Limitations of Oral Methotrexate at Doses >= 15 mg May Be Overcome with Subcutaneous Administration
    Baminger, H.
    [J]. JOURNAL FUR MINERALSTOFFWECHSEL, 2014, 21 (04): : 167 - 167
  • [33] Two-Year Results from the AMPLE Trial: Low Disease Activity and Association Between Remission and Changes in Physical Function and Radiographic Outcomes with Subcutaneous Abatacept or Adalimumab
    Fleischmann, Roy
    Schiff, Michael
    Weinblatt, Michael
    Maldonado, Michael
    Massarotti, Elena
    Yazici, Yusuf
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1475 - 1475
  • [34] Improved quality of life, work productivity, general activity and independence in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis: results from the AMPLE trial
    Fleischmann, R.
    Weinblatt, M.
    Schiff, M.
    Khanna, D.
    Rosenblatt, L.
    Maldonado, M.
    Furst, D.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 109 - 110
  • [35] IMPROVED QUALITY OF LIFE, WORK PRODUCTIVITY, GENERAL ACTIVITY AND INDEPENDENCE IN RESPONSE TO SUBCUTANEOUS ABATACEPT OR ADALIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM THE AMPLE TRIAL
    Fleischmann, R.
    Weinblatt, M.
    Schiff, M.
    Khanna, D.
    Rosenblatt, L.
    Maldonado, M.
    Furst, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 624 - 625
  • [36] HEAD-TO-HEAD COMPARISON OF TLL-018 AND TOFACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: INTERIM RESULTS FROM A PHASE IIA STUDY
    Zeng, X.
    Wu, C.
    Hu, J.
    Liu, S.
    Jiang, Z.
    Li, J.
    Wang, X.
    Liu, J.
    Liang, C.
    Yang, G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 200 - 200
  • [37] Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study
    Zeng, Xiaofeng
    Wu, Chanyuan
    Hu, Jiankang
    Liu, Shengyun
    Jiang, Zhenyu
    Li, Jingyang
    Wang, Xiaoxia
    Liu, Ju
    Yuan, Chaofan
    Yang, Guang
    Liang, Chris
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1684 - 1686
  • [38] CLINICAL RESPONSES BY BASELINE RA DISEASE DURATION IN THE AMPLE (ABATACEPT VERSUS ADALIMUMAB COMPARISON IN BIOLOGIC-NAIVE RA PATIENTS WITH BACKGROUND METHOTREXATE) TRIAL: 2-YEAR RESULTS
    Schiff, M.
    Weinblatt, M. E.
    Valente, R.
    van der Heijde, D.
    Citera, G.
    Maldonado, M. A.
    Fay, J.
    Fleischmann, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 387 - 388
  • [39] CORRELATION OF CLINICAL RESPONSE WITH PATIENT-REPORTED OUTCOMES IN THE AMPLE (ABATACEPT VERSUS ADALIMUMAB COMPARISON IN BIOLOGIC-NAIVE RA PATIENTS WITH BACKGROUND METHOTREXATE) TRIAL: 2-YEAR RESULTS
    Fleischmann, R.
    Weinblatt, M.
    Schiff, M.
    Khanna, D.
    Maldonado, M.
    Nadkarni, A.
    Fay, J.
    Furst, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 681 - 682
  • [40] DISTINCT BIOMARKERS ENRICH FOR CLINICAL RESPONSE TO TOCILIZUMAB (TCZ) AND ADALIMUMAB (ADA) IN ADACTA: A HEAD-TO-HEAD MONOTHERAPY STUDY IN PATIENTS (PTS) WITH METHOTREXATE (MTX)-IR RHEUMATOID ARTHRITIS (RA)
    Herman, A.
    Musselman, D.
    Fischer, S.
    Setiadi, A.
    Gabay, C.
    Kavanaugh, A.
    Klearman, M.
    Song, A.
    Townsend, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 206 - 206
12345